Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

about

Herbal medicines and nonalcoholic fatty liver disease Diffusion, convergence and influence of pharmaceutical innovations: a comparative study of Chinese and U.S. patents

P2860

Q26738524-96C539FE-A9F7-45F5-AC6F-C5CB8FDD2F3A Q57166689-6A3B0114-566B-4246-AF3B-383A343D7880

P2860

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

Item

http://www.wikidata.org/entity/Q38689651

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

@en

type

Item

label

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

@en

prefLabel

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

@en

P1476

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

@en

P2093

Hongliang Dai

http://www.w3.org/2001/XMLSchema#string

Hua Xie

http://www.w3.org/2001/XMLSchema#string

Huiyun Zhang

http://www.w3.org/2001/XMLSchema#string

Ke Cao

http://www.w3.org/2001/XMLSchema#string

Ping He

http://www.w3.org/2001/XMLSchema#string

Shaoheng He

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation.

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Anticholinergic agents in asthma and COPD.

Role of leukotriene receptor antagonists in the management of pediatric asthma: an update.

Is the asthma epidemic still ascending?

Asthma: pathogenesis and novel drugs for treatment.

24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.

Analysis of patents on anti-allergic therapies issued in China from 1988 to 2008.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.

P304

363-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2016.1136289

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26742645

http://www.w3.org/2001/XMLSchema#string

P921

patent

asthma

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

about

P2860

P2860

Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921